-- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency...
Fourth Quarter Revenue of $18.7 million and full year 2021 Revenue of $76.4 million, each increased 49% from the prior...
Leading proxy advisors Institutional Shareholders Services and Glass Lewis recommend HEXO shareholders vote FOR the Transaction Resolution and the Financing...
Organic growth in Q3 was 11% and reported revenue in DKK was up by 9% to DKK 4,835 million. EBIT...
9M 2020/21Interim financial results, 9M 2020/211 October 2020 - 30 June 2021Coloplast delivered Q3 organic growth of 11% and 33%...
August 18, 2021Announcement no. 14Q2 2021 Report Highlights Solid revenue growth in the first half of 2021 In the first half of...
Press Release Hørsholm, Denmark (August 18, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) yesterday published a notice to...
ORION CORPORATION PRESS RELEASE 18 AUGUST 2021 at 9.00 a.m. EEST Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration...
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC – – PFIC is...
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Financial results for the first half...
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA)...
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it...
MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it...
PORTLAND, Ore., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (“Chalice” or the “Company”), a premier consumer-driven...
Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research HospitalMedicinal mushroom compound with anticancer...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For...
COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative...
NOVATO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...
ALISO VIEJO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company, today...
